Overview
CODX market data
Price History
CODX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$35.25 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.94 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -6,753.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.26 – $46.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $10.4M · P/B 0.50 · P/S 14.43.
Company News
Co-Diagnostics Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga · Aug 13, 2026, 9:44 PM
Co-Diagnostics Q2 EPS $(1.46) Beats $(3.00) Estimate, Sales $166.131K Miss $166.500K EstimateBenzinga · Aug 13, 2026, 8:04 PM
Co-Diagnostics Announces FDA Submission Of Dual 510(k) With Concurrent CLIA Waiver Application For Co-Dx PCR Flu A/B & RSV Point-Of-Care TestBenzinga · Aug 6, 2026, 1:31 PM
8-K filing — Co-Diagnostics, Inc. (CODX)SEC EDGAR · Jul 31, 2026, 12:30 PM
Merck-Backed Lab Gets $8.5 Million to Fast-Track a Vaccine for a Rapidly Spreading Ebola OutbreakBenzinga · Jul 30, 2026, 1:02 PM
EXCLUSIVE: Co-Diagnostics India Joint Venture Completes Proof of Concept for Blood Test for Ebola on Co-Dx PCR Pro instrumentBenzinga · Jul 28, 2026, 11:42 AM
EXCLUSIVE: Co-Diagnostics Announces Successful Proof of Concept for Extraction-Free Ebola TestBenzinga · Jul 28, 2026, 11:41 AM
EXCLUSIVE: Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical StudiesBenzinga · Jul 28, 2026, 11:41 AM
Co-Diagnostics Amends Equity Distribution Agreement With Maxim Group For Common Stock Sale; May Offer And Sell Up To $7.90M Of Common StockBenzinga · Jul 27, 2026, 9:13 PM
Why Forte Biosciences Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving PremarketBenzinga · Jul 27, 2026, 9:09 AM